The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs-TKIs: A Retrospective Multicentric Study.

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Personalized Medicine Pub Date : 2024-09-27 DOI:10.3390/jpm14101030

Maria La Vecchia, Manuela Federico, Dario Aiello, Valentina Zagardo, Antonella Mazzonello, Lorella Testa, Leonarda La Paglia, Tiziana Bruno, Ivan Fazio

{"title":"The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs-TKIs: A Retrospective Multicentric Study.","authors":"Maria La Vecchia, Manuela Federico, Dario Aiello, Valentina Zagardo, Antonella Mazzonello, Lorella Testa, Leonarda La Paglia, Tiziana Bruno, Ivan Fazio","doi":"10.3390/jpm14101030","DOIUrl":null,"url":null,"abstract":"Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine-kinase inhibitor (TKI).Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI-TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6-12-18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety.Results: After a median follow-up of 24 months, 6-12-18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded.Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs-TKIs combination and SBRT upon oligoprogressive sites in mRCC.","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 10","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508468/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14101030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine-kinase inhibitor (TKI).

Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI-TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6-12-18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety.

Results: After a median follow-up of 24 months, 6-12-18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded.

Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs-TKIs combination and SBRT upon oligoprogressive sites in mRCC.

查看原文本刊更多论文

立体定向体外放射治疗 (SBRT) 在 ICIs-TKIs 治疗的寡进展性肾细胞癌 (RCC) 中的作用：一项多中心回顾性研究。

背景：这项多中心回顾性研究调查了立体定向体放射治疗（SBRT）在接受免疫检查点抑制剂（ICI）和酪氨酸激酶抑制剂（TKI）联合治疗期间出现少进展的转移性肾细胞癌（mRCC）患者（pts）中的应用情况：我们对2020年1月至2023年12月期间接受ICI-TKI联合治疗的34例少进展RCC患者进行了回顾性评估。对少进展转移性疾病的每个部位进行了 SBRT 治疗。SBRT后，患者接受后续临床评估。6-12-18个月的局部控制（LC）率和中位下线无治疗生存期（NEST-FS）是主要终点。次要终点为总反应率（ORR）、临床疗效和安全性：中位随访24个月后，6-12-18个月的LC率分别为100%、71%和43%，中位NEST-FS为20个月。ORR为90%，临床获益率为100%。没有记录到与SBRT相关的> G2不良事件：在我们的研究中，SBRT治疗少进展期mRCC是一种安全有效的治疗方法，能够保留现有的治疗方法。有必要进一步开展前瞻性研究，探讨ICIs-TKIs联合疗法和SBRT对mRCC少进展部位的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Personalized Medicine Medicine-Medicine (miscellaneous)

CiteScore

4.10

自引率

0.00%

发文量

1878

审稿时长

11 weeks

期刊介绍： Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.